Protocol Ledger

NCT07533019 · Phase II · RECRUITING

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Interventional Phase II clinical trial protocol NCT07533019 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-14 Enrollment: 66 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07533019
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)66 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07533019
Protocol FieldVerified Registry Value
NCT IdentifierNCT07533019
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment66 participants (ESTIMATED)
Registered Start Date2026-04-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07533019
Hospital Research SiteLocationSite Profile
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI